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Figure 1. Perception of Likelihood of cure with HSCT (P < 0.0001)
Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210 S193gender, disease type and type of transplant. The IgG levels in
the normal range and the IgG levels in the low range were
compared and analyzed based on type of transplant, disease,
age (at transplant), and gender.
Results: 76 charts were reviewed. 10 charts had no post-
transplant levels ever documented. 53 had normal IgG levels,
and 13 had low IgG levels post-transplant. Characteristics
common to the majority of patients with low IgG included
allogeneic transplantation and leukemia or lymphoma as a
diagnosis.
Conclusions: IVIG replacement is not indicated based on
levels of IgG in patients undergoing autologous stem cell
transplantation or who have an underlying diagnosis other
than leukemia or lymphoma.288
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Introduction: During hematopoietic stem cell trans-
plantation (HSCT), patients receive high dose chemotherapyTable 1
Longitudinal QOL and Mood by type of HSCT
Outcomes Type
HSCT
Week-1 Week-2 Week-3 P-Value
QOL, M Auto
Allo
105.8
101.1
95.4
97.6
93.7
96.3
P ¼ 0.0003
P[ 0.01
Fatigue, M Auto
Allo
34.4
39.0
27.0
34.9
27.3
29.7
P < 0.0001
P[ 0.01
HADS depression
> 7, N (%)
Auto
Allo
7 (23%)
3 (13%)
11 (37%)
6 (26%)
13 (43%)
6 (26%)
P ¼ 0.0003
P[ 0.05during a prolonged hospitalization and endure signiﬁcant
side effects in the hopes of curing their disease. While many
studies have focused on the long-term outcomes of patients
undergoing HSCT, the acute impact of hospitalization for
HSCT on patients’ quality of life (QOL), symptom burden, and
mood is unknown. Furthermore, data on patients’ perception
of their prognosis and likelihood of cure with HSCT are
lacking.
Methods: We conducted a prospective longitudinal study of
patients hospitalized at the Massachusetts General Hospital
for HSCT. At baseline and weeks 1, 2, and 3 of hospitalization,
we assessed QOL (Functional Assessment of Cancer Therapy-
Bone Marrow Transplantation [FACT-BMT]; higher scores
indicate better QOL), fatigue (FACT-Fatigue; higher scores
indicate less fatigue), and mood (Hospital Anxiety and
Depression Scale score> 7 on anxiety or depression subscale
considered clinically signiﬁcant). Using a 10-item question-
naire, we measured patients’ information preferences, and
perception of their prognosis.
Results: We enrolled 53 consecutive patients undergoing
autologous (n¼30), ormyeloablative allogeneic (n¼23) HSCT.
Patients’ QOL declined (FACT BMT mean scores week 1:107.5
àweek 2: 96.3 àweek 3: 94.8, p < 0.0001), and fatigue
increased (FACT Fatigue mean scores week1: 36.4 à week 2:
30.5 à week 3: 28.3, p < 0.0001) throughout hospitalization.
The proportion of patients with depression symptoms
increased from baseline to week 3 (18.9% to 35.8%; p¼0.002)
whereas the proportion of patients with anxiety symptoms
did not change signiﬁcantly from baseline (22.6%; p¼0.7).
These patterns remained consistent when data were strati-
ﬁed by the type of HSCT [Table 1]. Although 90.6% (48/53) of
patients stated that it is ‘extremely’ or ‘very’ important to
know about their prognosis, 76.0% (38/50) reported inaccu-
rate and overly optimistic perception of their prognosis
compared to their physicians (p < 0.0001) [Figure 1].
Conclusion: Patients with hematologic malignancies un-
dergoing HSCT report an overly optimistic perception of their
prognosis and experience signiﬁcant decline in QOL with
increasing symptom burden and rates of depression
throughout their hospitalization. Results suggest that in-
terventions to both improve the QOL and psychological
outcomes of patients hospitalized for HSCT and enhance
their prognostic awareness are clearly warranted.289
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Table 1
Characteristics of the Patients
Variable Number of
Patients
Gender
Female 67
Male 115
Diagnosis
Acute Leukemia 93
Chronic leukemia 48
Bone Marrow Failure 31
Lymphoma 5
Multiple Myeloma 4
Severe Combined
Immune Deﬁciency
1
Donor
Related 158
Unrelated 24
HSC Source
Bone Marrow 65
Peripheral Blood 109
Bone Marrow+ Peripheral
Blood
3
Umbilical Cord Blood 5
Conditioning Regimen
With Cy 174
Without Cy 8
Table
Donor source and infection risk (multivariate analysis)
Hazard ratio for UCB
vs. BM/PBSC (95% CI)
P-Value
Any infection 3.2 (2.3-4.4) <0.001
Bacterial 3.9 (2.8-5.5) <0.001
Viral 1.8 (1.1-2.7) 0.01
Fungal 2.7 (1.1-6.5) 0.03
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Infection is a major source of morbidity and mortality in
patients undergoing allogeneic hematopoietic cell trans-
plantation (HCT). Umbilical cord blood (UCB) recipients
appear to be at increased risk, and strategies to better
identify and mitigate infection are needed. To investigate
patterns and risk factors for infections by graft source (UCB
vs. bonemarrow (BM) or peripheral blood stem cells [PBSC]),
we conducted a single center retrospective study of 308
consecutive adult allogeneic HCT recipients transplanted
between 2006 - 2011 (BM 156, PBSC 103, UCB 49 patients).
All documented and presumed infections during the ﬁrst
year post-HCT were reviewed by a single reviewer. Among
BM/PBSC recipients, 53% received HCT using an unrelated
donor. Median age for UCB and BM/PBSC groups was 50 and
51 years. Diagnosis and disease status, HCT-CI scores, per-
formance status, and conditioning regimen intensity were
comparable among the two groups. Median time to neutro-
phil recovery (>500/mL) was 27 days in UCB and 13 days in
BM/PBSC recipients. The median length of transplant hos-
pitalization was 46 and 30 days, respectively. Bacterial in-
fections were more common for CB recipients (94% vs. 63%, P
< 0.001), without signiﬁcant differences in viral, fungal, or C.
difﬁcile infections. The day of ﬁrst infection was notably
earlier in the UCB recipients (median 6 vs. 30 days, P <
0.001), and >1 infection (bacterial, viral or fungal) occurred
in 65% of UCB vs. 34% of BM/PBSC recipients. Incidences of
acute and chronic GVHD were similar between groups,
however CB recipients were less likely to have GVHD prior to
diagnosis of bacterial (11% vs. 35%, P < 0.001) or viral infec-
tion (36% vs. 59%, P ¼ 0.03). On multivariate analysis, UCB
donor source remained a signiﬁcant risk factor prognostic for
all infection types (Table). Bacterial infection was associated
with increased mortality (HR 2.92, P < 0.001), as was fungal
infection (HR 2.58, P < 0.001), but not viral infection/reac-
tivation. In conclusion, UCB recipients have increased risk of
infections compared to BM/PBSC. Infections occurred earlier
and before engraftment in UCB recipients, suggesting the
role of factors other than prolonged neutropenia in their
pathogenesis. The association of donor source and post-HCT
infections is likely multifactorial.Ablative 164
Reduced intensity 18
Response
Complete Remission 147
Partial Remission 4
Not assessed 31
HC
Grade 1 83
Grade 2 43
Grade 3 42
Grade 4 14290
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Hemorrhagic cystitis is one of the important causes of
morbidity, which may occur after allogeneic hematopoietic
stem cell transplantation (allo-HSCT). Using high dose
cyclophosphamide (Cy) as the conditioning regimen is
associated with early-onset hemorrhagic cystitis (HC). It is
reported that the administration of mesna protects against
early-onset HC, caused by Cy. However, late-onset HCmay be
seen frequently due to viral infections, mostly cytomegalo-
virus (CMV) and BK/JC virus.
We have retrospectively analyzed 182 patients, who devel-
oped HC after allo-HSCT, from 1988 to 2013. Characteristics
of the patients were shown in Table 1.
We also present 44 HC patients having detailed data between
2010 and 2013. In these 44 patients median date of the
development of HC was calculated as 46 days (4-144). We
deﬁned early-onset HC is HCwhen developed before the 21st
day of HSCT, which consists of 7 patients and late-onset HC is
HC when developed afterwards of the 21st day of HSCT,
which consists of 37 patients. Graft versus Host Disease and
HC developed simultaneously in 28 patients.
Patients were initially treated with intravascular hydration
and constant bladder irrigation. This treatment was effective
within most of the patients. The treatment failed in 11 cases
and 5 of them underwent a cystoscopy for evacuation of
blood clots. Two patients infected with CMV and 9 patients
